logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Reata Pharmaceuticals: Good News for the Prohost Pick

Reata Pharmaceuticals Announcement Regarding the NDA for Omaveloxolone for Friedreich’s Ataxia Reata Pharmaceuticals (RETA) announced that the U.S. Food and Drug Administration ( FDA ) does not plan to hold an advisory committee meeting in connection with its review of...

Read More

October 14, 2022

0

Gilead and MacroGenics Announce Oncology Collaboration to Develop Promising Bispecific Antibodies

Gilead Sciences and MacroGenics Collaboration Announcement Gilead Sciences ( GILD ) and MacroGenics ( MGNX ) announced an exclusive option and collaboration agreement to develop MGD024 using MacroGenics DART® platform, and two additional bispecific research programs. The collaboration agreement grants...

Read More

October 17, 2022

0

Gilead Therapeutics and Genesis Therapeutics Announced Strategic Collaboration to Discover and Develop Novel Therapies

Gilead Sciences and Genesis Therapeutics Gilead Sciences ( GILD ) and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. Genesis Therapeutics is pioneering...

Read More

September 10, 2024

0

Why IVERIC bio Rallied Today

IVERIC bio's Rally IVERIC Bio ( ISEE ) announced that the U.S. ( FDA ) has granted Breakthrough Therapy designation for avacincaptad pegol ( ACP ), also known as Zimura®. Zimura is a novel investigational complement C5 inhibitor aimed at treating...

Read More

November 18, 2022

0

Madrigal Pharmaceuticals and Akero Therapeutics: After Having No Treatment for NASH, We Now Have Two Products Expected to be Approved

Treatments for NASH Madrigal Pharmaceuticals ( MDGL ) is the second company after Akero Therapeutics ( AKRO ) to announce positive top-line late results for Nonalcoholic steatohepatitis (NASH). Its product resmetirom - a liver-directed selective thyroid hormone receptor agonist has...

Read More

December 19, 2022

0

Why Kala Pharmaceuticals Stock is Soaring

Kala Pharmaceuticals  Kala Pharmaceuticals ( KALA )  announced today that the U.S. FDA has accepted the investigational new drug application ( IND ) for its lead product candidate, KPI-012, a human Mesenchymal Stem Cell Secretome ( MSC-S ) for the...

Read More

December 28, 2022

0

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

CytomX and Moderna in the NEWS On January 05, 2023,  CytomX Therapeutics ( CTMX ) and Moderna Inc ( MRNA )  announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna’s mRNA technologies and CytomX’s Probody therapeutic...

Read More

January 5, 2023

0

Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise

Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise Editas Medicine, Inc. ( EDIT ) , announced that it has entered into a definitive agreement with the private Shoreline Biosciences (Shoreline) to license Editas Medicine’s proprietary SLEEK (SeLection by Essential-gene Exon...

Read More

January 19, 2023

0

Merck: KEYTRUDA Plus Chemo as First-Line Treatment for Stage III-IV or Recurrent Endometrial Carcinoma

Merck KEYTRUDA Announcement Merck ( MRK ) announced today that Phase 3 NRG-GY018 trial evaluating KEYTRUDA in combination with chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression-free survival ( PFS ) in patients with stage III-IV or recurrent...

Read More

February 3, 2023

0

Why Travere Therapeutics' Stocks Did Not Fall During This Tuesday's Bad Market

The Bear Market The volatility in the Bear stock market continues to plunge the values of biotech stocks. The Bear market is sucking investors’ capitals who bet on firms with future growth potential based on early, mid term and late...

Read More

February 22, 2023

0

  • Previous
  • 1
  • 2
  • ...
  • 162
  • 163
  • 164
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy